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INTRODUCTION
Anthracycline and taxane have been very essential drugs in the 
treatment of breast cancer patients in neoadjuvant and adju-
vant settings. In particular, anthracycline has been very widely 
used in spite of its major limitation, cardiotoxicity [1-3]. Some 
studies have reported that an anthracycline-based regimen 
had more favorable results in HER2 overexpression tumors. 
Recently, it has been demonstrated that this result is mediated 
by topoisomerase IIα (TOP2A). Anthracycline binds to TOP2A 
and stabilizes DNA double strand breaks, resulting in cell cycle 
arrest and apoptosis. The Top2A gene is located close to the 
HER2 gene on chromosome 17, and TOP2A gene co-amplica-
tion has been found in about 40% of HER2-positive type breast 
cancers [4,5]. Nevertheless, anthracycline is still a fascinating 
chemotherapeutic regimen for HER2-positive type breast can-
cer patients. Anthracycline-based chemotherapy has been used 
as a good neoadjuvant and adjuvant treatment choice for both 
HER2-positive type and triple negative breast cancers (TNBC). 
It has been shown to produce higher pathological complete     
response (pCR) rates for TNBC in a neoadjuvant setting and 
better survival rates in an adjuvant setting [6-10].
Several studies have been conducted on the usefulness of the 
adenosine triphosphate-based chemotherapy response assay 
(ATP-CRA) in breast cancer [11-13]. This assay measures intra-
cellular ATP, the basic energy source for living cells, which rap-
idly disappears when cells lose viability. The ATP-CRA has an 
advantage of a high success rate in primary culture and require 
only a small number of cells [12-16]. Thus, it is widely used as 
a chemosensitivity assay modality for the treatment of various 
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Purpose: A chemotherapy response assay test is performed to 
evaluate the degree of tumor growth inhibition by a chemothera-
peutic agent. Several studies have been done on its usefulness; 
however, to the best of our knowledge, only a few studies concern-
ing the relationship between chemotherapy response assay test 
results and breast cancer patients’ prognoses have been con-
ducted. Thus, we performed this study to analyze this relationship. 
Methods: Among breast cancer patients who underwent curative 
surgery and neoadjuvant or adjuvant chemotherapy between 
August 2004 and December 2009, 102 were enrolled in this study. 
Chemotherapeutic regimens for patients were doxorubicin plus 
taxane or doxorubicin plus cyclophosphamide followed by tax-
ane. We divided these patients into two groups (sensitive group 
[n=19] and resistant group [n=83]) and analyzed the relationship 
between chemosensitivity results and patient prognosis. Results: 
The sensitive group was associated with poor disease-free sur-
vival (DFS) (p=0.003) and overall survival (OS) (p<0.001). No sig-
nificant differences were observed in tumor histology (p=0.548), 
tumor size (p=0.479), number of metastatic lymph nodes (p= 
0.326), histologic grade (p=0.077), or nuclear grade (p=0.216) 
between the two groups. However, in respect to molecular sub-
type, the HER2-positive type and triple negative breast cancer 
were more frequently observed in the sensitive group (p=0.001). 
In a univariate and multivariate analysis for DFS, doxorubicin sen-
sitivity was significantly associated with a poor prognosis (p< 
0.05). Conclusion: Better chemosensitivity results are associated 
with a poor prognosis in breast cancer patients who have under-
gone anthracycline- and taxane-based chemotherapy, however, 
examination of additional cases and the use of a longer study 
period are needed.
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cancers in clinical settings. However, only a few studies have 
been performed concerning the relationship between chemo-
therapy response assay test results and breast cancer patient 
prognosis [17]. We performed this study to evaluate the ATP-
CRA results and prognoses for breast cancer patients who had 
undergone anthracycline and taxane based chemotherapy.
METHODS
From August 2004 to December 2009, we performed ATP-
CRA for 257 patients with breast cancer at the Department of 
Surgery, Ewha Womans University Mok-dong Hospital, Seoul, 
Republic of Korea. Among these patients, we enrolled patients 
who had undergone curative surgery and had received doxo-
rubicin plus taxane or doxorubicin plus cyclophosphamide 
followed by taxane chemotherapy. A total of 102 patients were 
included in this study. The mean follow-up duration was 29.8± 
15.6 months.
For ATP-CRA, two specimens were taken per patient by 
true-cut biopsy or core needle biopsy. We stored these tissues 
in Hank’s Balanced Salt Solution (HBSS; Gibco BRL, Rockville, 
USA) composed of 100 IU/mL of penicillin (Sigma, St. Louis, 
USA), 100 mg/mL of streptomycin (Sigma), 100 mg/mL of gen-
tamicin (Gibco BRL), 2.5 mg/mL of amphotericin B (Gibco 
BRL), and 5% fetal bovine serum (Gibco BRL). The stored tumor 
tissues were sent to a commercial laboratory center for deter-
mination of their sensitivities to each chemotherapeutic regi-
men. The most commonly used chemotherapeutic regimens 
and their concentrations were as follows: 5-FU (10 µg/mL), 
paclitaxel (8.5 µg/mL), docetaxel (3.7 µg/mL), doxorubicin (1.5 
µg/mL), methotrexate (0.37 µg/mL), and cyclophosphamide 
(4-OH-cyclophosphamide, 1.2 µg/mL). If sufficient cancer cells 
were available to determine their sensitivity, these cells were 
tested with three treated drug concentrations (TDC; 0.2×, 1×, 
5×). If not, their ATP–CRA results were determined using 
only one TDC (1×). Doxorubicin and taxane sensitivities were 
determined using a cell death ratio cut-off of 40% and 24%, 
respectively, on the basis of TDC (1×). Receiver operating 
characteristic (ROC) curves were used to determine these cut-
off values. 
The doxorubicin sensitive group was compared to the resis-
tant group with respect to their clinical characteristics (age, op-
eration methods, chemotherapy type, and chemotherapeutic 
regimen), pathologic results, disease-free survival (DFS), and 
overall survival (OS). In respect to estrogen receptor (ER) status, 
we defined ER-positive when more than 10% of cancer cells were 
stained with more than 1+ of intensity. In the case of HER2-
positive, it was defined as c-erb-B2+++ or when the ratio of 
HER2 loci/chromosome 17 centromeres was more than 2.2. 
Univariate and multivariate anaylsis were performed to identify 
whether ATP-CRA results could be an independent prognos-
tic factor for DFS. 
All data were analyzed using SPSS version 17.0 (SPSS Inc., 
Chicago, USA). Statistical significance was analyzed using the 
Student’s t-test and Pearson’s chi-square test. DFS and OS were 
calculated using the Kaplan-Meier method and log-rank test. 
Cox’s proportional hazards regression model was used for uni-
variate and multivariate analyses, and p-values <0.05 were 
considered statistically significant.
RESULTS
Patient characteristics
During the study period, a total number of 257 ATP-CRAs 
were performed in our hospital and among these, 102 were 
included in this study. We divided these patients into two groups 
according to doxorubicin sensitivity. There were 19 patients in 
the sensitive group with a mean age of 49.0±9.3 years (range, 
29 to 69 years) and 83 patients in the resistant group with a 
mean age of 46.8±8.8 years (range, 30 to 69 years). No signifi-
cant differences were noted with regard to patient age, opera-
tion type, or chemotherapeutic regimen between the two groups. 
However, there were more patients who received neoadjuvant 
chemotherapy (p=0.021), and more patients who were sensi-
tive to taxane in the doxorubicin sensitive group (p=0.001, 
Table1). 
Pathologic results according to doxorubicin sensitivity
The pathologic results of all patients according to doxorubicin 
sensitivity have been presented in Table 2. No significant differ-
Table 1. Patients’ demographics according to doxorubicin sensitivity
Variables
Sensitive  
group (n=19)
Resistant  
group (n=83)
p-value
Age (yr)* 49.0±9.3 46.8±8.8 0.365
Operation 0.430
   BCS   5 (26.3) 32 (38.6)
   MRM 14 (73.7) 51 (61.4)
Chemotherapy type 0.021
   Neoadjuvant   9 (47.4) 17 (20.5)
   Adjuvant 10 (52.6) 66 (79.5)
Chemotherapy regimen 0.097
   AC followed by T 13 (68.4) 71 (85.5)
   AT   6 (31.6) 12 (14.5)
Taxane sensitivity 0.001
   Sensitive 13 (68.4) 21 (25.3)
   Resistant   6 (31.6) 62 (74.7)
Values are presented as mean±SD or number (%).
BCS=breast conserving surgery; MRM=modified radical mastectomy; AC= 
doxorubicin+cyclophophmide; T=taxane; AT=doxorubicin+taxane.
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ences were observed in histologic type, HER2-positive status, 
histologic grade, nuclear grade, tumor size, and nodal status 
between the two groups. However, HER2-positive type cancer, 
TNBC, and ER-negative cancers were more frequently observed 
in the sensitive group (p<0.05). All patients had metastases of 
axillary lymph nodes (LNs) or lymphovascular invasion.
Table 2. Pathologic results according to doxorubicin sensitivity
Variables
Sensitive  
group (n=19)
Resistant  
group (n=83)
p-value
Histology 0.548
   IDC   19 (100.0) 78 (94.0)
   ILC 0 4 (4.8)
   Others 0 1 (1.2)
Molecular subtype 0.001
   Luminal A   2 (10.5) 51 (61.5)
   Luminal B   5 (26.3) 10 (12.0)
   HER2 type   3 (15.8) 8 (9.6)
   TNBC   9 (47.4) 14 (16.9)
Estrogen receptor 0.006
   Positive   7 (36.8) 61 (73.5)
   Negative 12 (63.2) 22 (26.5)
HER2 status 0.082
   Positive   8 (42.1) 18 (21.7)
   Negative 11 (57.9) 65 (78.3)
Histologic grade 0.077
   1 0 17 (20.5)
   2   9 (47.4) 35 (42.2)
   3   9 (47.4) 26 (31.3)
   Unknown 1 (5.2) 5 (6.0)
Nuclear grade 0.216
   1 0 10 (12.0)
   2   8 (42.1) 37 (44.6)
   3 10 (52.7) 32 (38.6)
   Unknown 1 (5.2) 4 (4.8)
Tumor size (cm) 0.479
   ≤2   7 (36.8) 31 (37.3)
   >2, ≤5   9 (47.4) 46 (55.4)
   >5   3 (15.8) 6 (7.2)
No. of metastatic LNs 0.326
   0   2 (10.5) 8 (9.6)
   ≤3 11 (57.9) 40 (48.2)
   4-9   2 (10.5) 25 (30.2)
   ≥10   4 (21.1) 10 (12.0)
Values are presented as number (%).
IDC=invasive ductal carcinoma; ILC=invasive lobular carcinoma; TNBC=triple 
negative cancer; LNs=lymph nodes.
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Figure 1. Disease-free survival according to doxorubicin sensitivity.
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Figure 2. Overall survival according to doxorubicin sensitivity.
Table 3. Univariate and multivariate analysis for DFS in all patients
Variables
Univariate analysis Multivariate analysis
CI p-value CI p-value
ER status 0.147-1.244 0.109 0.207-2.208 0.517
HER2 status 0.468-4.295 0.538 0.191-2.413 0.549
Histologic grade 0.880-4.915 0.095 0.484-5.192 0.446
Nuclear grade 0.860-6.351 0.096 0.297-4.482 0.837
Tumor size 0.694-3.276 0.300 0.335-1.884 0.602
No. of metastatic LNs 0.997-3.301 0.051 1.203-4.771 0.013
Doxorubicin sensitivity   1.286-13.827 0.034   1.541-17.029 0.008
Taxane sensitivity 0.721-6.045 0.175
DFS=disease free survival; CI=confidence interval; ER=estrogen receptor; LNs=lymph nodes.286  AnbokLee,etal.
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Patient prognosis according to doxorubicin sensitivity
In our study, a total of 14 cancer recurrences were observed, 
7 of which were in the sensitive group. Among these, 3 patients 
died of breast cancer. We compared DFS and OS according to 
doxorubicin sensitivity. In the sensitive group, DFS and OS were 
significantly worse than those in the resistant group (Figures 1, 2).
Univariate analysis for DFS indicated that only doxorubicin 
sensitivity was significantly associated with high risk of recur-
rence (p=0.006; confidence interval [CI], 1.550-12.994). With 
respect to taxane sensitivity, no significant effect was observed 
on DFS (p=0.175; CI, 0.721-6.045). We performed a multivar-
iate analysis for significant factors in univariate analysis and 
established breast cancer prognostic factors, and according to 
the results, a higher nodal stage (p=0.013; CI, 1.203-4.771) and 
doxorubicin sensitivity (p=0.008; CI, 1.541-17.029) were asso-
ciated with poor DFS (Table 3).
DISCUSSION
Anthracycline and taxane have been the most commonly 
used chemotherapeutic agents for breast cancer patients. In 
neoadjuvant treatment, it had been reported that anthracycline-
based chemotherapy produced more superior treatment results 
in TNBC/basal like breast cancer (BLBC) compared to non-
TNBC/BLBC. Furthermore, these results were improved by 
adding taxane to the anthracycline [8-10]. With respect to     
adjuvant settings, anthracycline-based chemotherapy has been 
effective for patients with HER2-positive type and positive 
TOP2A and also for TNBC patients when compared with CMF 
chemotherapy [18,19]. In HER2 over-expression tumors, the 
effect of anthracycline has been shown to be mediated by   
TOP2A. Anthracycline binds to TOP2A and stabilizes DNA 
double strand breaks, which results in cell cycle arrest and apop-
tosis, and it has been known that the TOP2A gene is located 
close to the HER2 gene on chromosome 17. TOP2A gene     
co-amplification has been found in about 40% of HER2-posi-
tive type breast cancers [4,5]. 
Among the various chemosensitive assay tests, ATP-CRA 
showed a relatively high diagnostic accuracy for predicting   
response to drugs, and this result was similar with or superior 
to those of other tests. The ATP-CRA measured intracellular 
ATP, which is a basic energy source for living cells, and which 
rapidly disappears when cells lose viability. This has an advan-
tage of a high success rate in primary culture, in addition to 
requiring only a small number of cells. Therefore ATP-CRA 
has been widely used as a chemosensitivity assay modality for 
the treatment of various cancers [11-16]. Among studies on the 
correlation between ATP-CRA results and patient prognosis, 
Konecny et al. [20] reported that patients with chemosensitivity 
had a favorable prognosis (progression-free survival [PFS], OS) 
compared to patients with chemoresistance in primary FIGO 
III ovarian cancer. In breast cancer, Ahn et al. [17] reported that 
the doxorubicin sensitive group had a lower early recurrence rate. 
It has been previosly reported that in neoadjuvant chemo-
therapy, TNBC/BLBC, and HER2-positive type are more sen-
sitive to anthracycline and taxane chemotherapy. Despite this 
result, these cancer subtypes have worse prognoses among   
residual lesions after chemotherapy [7-10]. Furthermore, it 
has been suggested that ER-negative cancers showed a better 
response to primary chemotherapy than ER-positive cancers 
[21,22]. Actually, in our study, there were relatively more HER2-
positive type, TNBC, ER-negative, and taxane-sensitive breast 
cancer patients in the sensitive group compared to those in the 
resistant group (Table 2). Thus, we think that doxorubicin sen-
sitivity can reflect tumor biology, and more tumor types with 
a worse prognosis may be found in the doxorubicin sensitive 
group. For this reason, prognoses of patients in the sensitive 
group might be poorer than those of the resistance group. We 
determined doxorubicin and taxane sensitivity using cell death 
ratio cut-offs of 40% and 24%, respectively. 
Ahn et al. [17] suggested that tumor recurrence within first 
two years after operation was associated with chemotherapy 
resistance and therefore, we determined cut-off values for doxo-
rubicin and taxane using ROC curves based on their study. 
However, these cut-off values have been a little bit different in 
every study, and a consensus value has yet to be established [12]. 
Thus, we believe that additional studies addressing this issue 
should be performed, as well as studies utilizing a larger num-
ber of patients.
We performed univariate and multivariate analyses to deter-
mine whether the doxorubicin sensitivity could be an indepen-
dent prognostic factor. Univariate analysis for DFS indicated 
that only doxorubicin sensitivity was associated with poor DFS 
(p=0.006; CI, 1.550-12.994) whereas in the multivariate anal-
ysis, doxorubicin sensitivity (p=0.008; CI, 1.541-17.029) and 
higher nodal stage (p=0.013; CI, 1.203-4.771) were associated 
with poor DFS. 
In the present study, we could not find any significant rela-
tionship between well known prognostic factors of breast cancer 
and prognosis except LN status. This may have been due to a 
small number of patients (n=102) and relatively short follow-
up period (29.8±15.6 months). With respect to OS, we could 
not get a meaningful result because of the limited number of 
cancer-related deaths in the univariate and multivariate analysis.
There are some limitations in our study. This study was per-
formed according to doxorubicin sensitivity, although all pa-
tients were treated with combined or sequential chemotherapy 
(doxorubicin and taxane or doxorubicin and cyclophospha-CanThisAssayPredictthePrognosisofBreastCancerPatients? 287
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mide followed by taxane). As such, the way to reflect the ATP-
CRA results of cyclophosphamide and taxane posed a chal-
lenge. As the ATP-CRA is an in vitro test, we could not exactly 
predict the in vivo response of combined or sequential chemo-
therapy. Thus, we included taxane sensitivity in the univariate 
analysis to confirm its effect on DFS to determine that there 
were no significant effects of taxane on DFS (p=0.175; CI, 0.721-
6.045). However, a study on this problem might be needed to 
determine a more precise relationship between ATP-CRA and 
patient prognosis. Another limitation of current study was the 
relatively small number of patients and short length of the study 
period, as previously mentioned. We feel that studies involving 
a large number of cases and employing a longer study period 
are needed to determine the relationship between the ATP-
CRA and patient prognosis.
The main purpose of a chemosensitive test is to choose the 
most effective chemotherapeutic agent or exclude non-effec-
tive agents for cancer patients. Additionally, if prognostic infor-
mation for those patients is made available in this study, it may 
present a further benefit of this test. According to our study, 
the doxorubicin sensitive group was related with poor DFS and 
OS. Additionally, most of the patients in the sensitive group 
were HER2-positive types and TNBC. Considering these facts, 
we could predict the prognosis of patients who received anthra-
cycline and taxane based chemotherapy with doxorubicin sensi-
tivity on the basis of ATP-CRA results. However, as mentioned, 
higher numbers of patients and longer study periods are needed, 
as well as further studies on the precise cut-off values for drug 
sensitivity, and the most effective way to show the results of 
combined or sequential chemotherapy.
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